Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma
Bristol Myers Squibb and Bluebird…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a…
Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical…
Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
A novel genetic test could help identify people with…
Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide),…
FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell…
